Arbutus Biopharma (ABUS) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 178.0% versus a loss of 4.3%. Immix Biopharma is the larger company by market cap ($661.6 million vs $646.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | IMMX |
|---|---|---|
| Share price | $4.22 | $7.98 |
| Market cap | $646.82M | $661.57M |
| 1-day change | -1.63% | -8.06% |
| YTD return | -12.27% | +52.58% |
| 1-year return | -4.31% | +178.05% |
| 5-year return | +4.71% | — |
| P/E ratio (TTM) | 5.34 | — |
| EPS (TTM) | $0.79 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | — |
| Revenue growth (YoY) | +128.21% | — |
| Net income (latest FY) | $-33.50M | $-29.40M |
| Operating margin | -270.96% | — |
| Net margin | -237.88% | — |
| 52-week high | $5.45 | $15.10 |
| 52-week low | $3.50 | $2.71 |
| Distance from 52-week high | -22.57% | -47.15% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +27.96% | +204.51% |
| Average volume | 4.81M | 1.65M |
| Shares outstanding | 153.28M | 82.90M |
| Employees | 19 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed ABUS by 182.4 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ABUS vs IMMX FAQ
Which is bigger, Arbutus Biopharma or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $661.57M compared with $646.82M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or IMMX?
IMMX returned +178.05% over the past 12 months, compared with -4.31% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.